DrugPatentWatch Database Preview

Details for Patent: 5,763,476

Which drugs does patent 5,763,476 protect, and when does it expire?

Patent 5,763,476 protects SAPHRIS and is included in one NDA.

Protection for SAPHRIS has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-four patent family members in twenty-one countries.

Summary for Patent: 5,763,476

Title:	Sublingual or buccal pharmaceutical composition
Abstract:	The invention relates to a sublingual or buccal pharmaceutical composition comprising trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino-[4 ,5-c]pyrrole or a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable auxiliaries suitable for use in sublingual or buccal compositions, and the use thereof for the manufacture of a sublingual or buccal pharmaceutical composition for the treatment of mental disorders, such as psychosis and schizophrenia.
Inventor(s):	Delbressine; Leonardus Petrus Carla (Nijmegen, NL), Wieringa; Johannes Hubertus (Heesch, NL)
Assignee:	Akzo Noble N.V. (Arnhem, NL)
Application Number:	08/693,064
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 5,763,476
Patent Claim Types: see list of patent claims	Composition; Compound; Use; Process; Formulation;

Drugs Protected by US Patent 5,763,476

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Forest Labs Llc	SAPHRIS	asenapine maleate	TABLET;SUBLINGUAL	022117-003	Mar 12, 2015		RX	Yes	No	➤ Sign Up	➤ Sign Up			Y		➤ Sign Up
Forest Labs Llc	SAPHRIS	asenapine maleate	TABLET;SUBLINGUAL	022117-001	Aug 13, 2009		RX	Yes	No	➤ Sign Up	➤ Sign Up			Y		➤ Sign Up
Forest Labs Llc	SAPHRIS	asenapine maleate	TABLET;SUBLINGUAL	022117-002	Aug 13, 2009		RX	Yes	Yes	➤ Sign Up	➤ Sign Up			Y		➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

Foreign Priority and PCT Information for Patent: 5,763,476

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	94200521	Mar 02, 1994

PCT Information
PCT Filed	March 01, 1995	PCT Application Number:	PCT/EP95/00765
PCT Publication Date:	September 08, 1995	PCT Publication Number:	WO95/23600

International Family Members for US Patent 5,763,476

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	167057	➤ Sign Up
Australia	1947895	➤ Sign Up
Australia	692530	➤ Sign Up
Brazil	1100625	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Summary for Patent: 5,763,476

Foreign Priority and PCT Information for Patent: 5,763,476

For more information try a trial or see the plans and pricing